Liquidity

Proteonomix Inc (OTC:PROT) a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, recently reported that the company has executed a joint venture agreement with a group of investors that will create a new stem cell treatment and research facility in the United Arab Emirates. The Investor Group has committed to invest $5 million on or before September 10, 2010. The Joint Venture company, XGen Medical LLC (”XGen”), a Nevis Island limited liability company, will be owned 51% by Proteonomix and 49% by the Investor Group. Due to confidentiality and competitive reasons, the Investor Group has requested to remain anonymous for the present. The Investor Group is not related directly and/or indirectly to the Company, its management, its board of directors and/or its current shareholders.

PROT is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging skin care products.

Arena Pharmaceuticals, Inc. (Nasdaq:ARNA) and Eisai Inc. recently reported that the Food and Drug Administration (FDA) has notified the company of the confirmed scheduling of an Endocrinologic and Metabolic Drugs Advisory Committee meeting on September 16, 2010, for the review of the lorcaserin New Drug Application (NDA). Lorcaserin which Arena discovered and has developed for weight management, is intended for overweight and obese patients who have at least one weight related co-morbid condition.

ARNA is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena’s most advanced drug candidate, lorcaserin, is intended for weight management and has completed a pivotal Phase 3 clinical trial program.

Cleveland BioLabs, Inc. (NASDAQ:CBLI) recently reported that the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (DHHS) exercised the $4.1 million fourth milestone-based option on the Company existing contract under the Broad Agency Announcement titled, “Therapies for Hematopoietic Syndrome, Bone Marrow Stromal Cell Loss, and Vascular Injury Resulting from Acute Exposure to Ionizing Radiation,” for selected tasks in the advanced development of Protectan CBLB502. The value of the contract, originally awarded in September 2008, is $15.6 million, including an increase in the first milestone-based option, which was exercised in September 2009.

CBLI is a drug discovery and development company leveraging its proprietary discoveries around programmed cell death to develop treatments for cancer and protection of normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Radiobiology Research Institute.

Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)

Proteonomix Inc (OTC:PROT) recently reported that on August 10, 2010, the Registrant entered into an agreement with a group of investors that will create a new stem cell treatment and research facility in the United Arab Emirates (U.A.E.). The Investor Group has committed to invest $5 million on or before September 10, 2010. The Joint Venture company, XGen Medical LLC (”XGen”), a Nevis Island limited liability company, will be owned 51% by Proteonomix and 49% by the Investor Group.

The Investor Group assumes a variety of operational duties under the agreement, including some regulatory responsibility in the U.A.E., physician recruitment and cooperative management of the local entity. The Investor Group’s $5 million cash investment includes the purchase of $1 million of cellular material from Proteonomix.

Additionally, as part of the agreement Proteonomix will license to XGen, both a use and treatment license in the UAE, as well as a license to manufacture the cellular material. The agreement also anticipates the formation of treatment facilities in other locations to be jointly agreed upon between the Company and the Investor Group. Each new facility would require the Investor Group to contribute a minimum investment of $5 million.

XGen will maintain exclusive distribution rights of Proteoderm in the U.A.E. provided the Joint Venture purchases a minimum order of 5,000 units the first year, and increases purchases at a rate of 20% per annum until reaching 10,000 units per year.

PROT is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging skin care products.

National Research Corporation (NASDAQ:NRCI) recently reported it has acquired, via stock purchase agreement, Outcome Concept Systems, Inc. (OCS), a privately-held healthcare informatics firm, in an all-cash transaction. OCS is a leading provider of clinical, financial and operational benchmarks and analytics to home care and hospice providers. OCS works with over 2,000 care providers throughout the United States and is based in Seattle, Washington. OCS delivers what it believes to be, the most robust benchmarking database available to the home care and hospice marketplace, complete with web-based tools, analytics, and knowledge resources to support improvement in organizational performance through evidence-based practice.

NRCI is a healthcare research and quality improvement firm offering performance measurement and improvement services to health plans, hospitals, health care systems, physicians, and other healthcare organizations. Dedicated solely to the healthcare industry, NRC is a leading provider of ongoing performance measurement, improvement, analysis and tracking services to healthcare organizations. NRC is a technical innovator, with state-of-the-art systems for large scale research projects and cutting edge web-based tools for improving service quality.

Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) recently reported their financial results for the second quarter 2010 and presented a quarterly update on the Company’s development progress.

Recent Highlights:

* Reported results from Study 303 in which patients maintained statistically significant 3.2 unit improvement in orthostatic hypotension questionnaire (OHQ) composite scores following long-term NORTHERA™ (droxidopa) treatment in neurogenic orthostatic hypotension (NOH) (p<0.001);
* Initiated Northera Study 306, a pivotal Phase III trial in Parkinson’s disease patients with symptomatic neurogenic orthostatic hypotension;
* Completed enrollment in Northera Study 301, a pivotal Phase III trial in neurogenic orthostatic hypotension, bringing final enrollment to 167 patients and further increasing the power of the study to 90%;
* Reported positive interim analysis of Phase II study of droxidopa in fibromyalgia by independent data monitoring committee supporting efficacy of novel droxidopa/carbidopa combination therapy; and
* Submitted additional CH-4051 preclinical data and revised protocol for Phase II trial in rheumatoid arthritis to the U.S. Food and Drug Administration (FDA).

CHTP is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases. Chelsea’s most advanced drug candidate, Droxidopa, is an orally active synthetic precursor of norepinephrine initially being developed for the treatment of neurogenic orthostatic hypotension. In addition to Droxidopa, Chelsea is also developing a portfolio of metabolically inert oral antifolate molecules engineered to have potent anti-inflammatory and anti-tumor activity to treat a range of immunological disorders, including two clinical stage product candidates: CH-1504 and CH-4051. Preclinical and clinical data suggest superior safety and tolerability, as well as increased potency versus methotrexate (MTX).

Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)

ALPHARETTA, Ga., Aug. 14 (CRWENEWSWIRE) — Wright County Egg of Galt, Iowa, is voluntarily recalling specific Julian dates of shell eggs produced by their farms because they have the potential to be contaminated with Salmonella, a food-borne bacteria. The company is making this voluntary recall of products because testing at the company’s farm showed some of the eggs may contain the bacteria.

Consumers should return the eggs in the original carton to the store where they were purchased for a full refund. Eggs affected by this recall were distributed to food wholesalers, distribution centers and foodservice companies in California, Illinois, Missouri, Colorado, Nebraska, Minnesota, Wisconsin and Iowa. These companies distribute nationwide.

Eggs are packaged under the following brand names: Lucerne, Albertson, Mountain Dairy, Ralph’s, Boomsma’s, Sunshine, Hillandale, Trafficanda, Farm Fresh, Shoreland, Lund, Dutch Farms and Kemps. Eggs are packed in varying sizes of cartons (6-egg cartons, dozen egg cartons, 18-egg cartons) with Julian dates ranging from 136 to 225 and plant numbers 1026, 1413 and 1946. Dates and codes can be found stamped on the end of the egg carton. The plant number begins with the letter P and then the number. The Julian date follows the plant number, for example: P-1946 223.

Consumers are reminded that properly storing, handling and cooking eggs should help prevent food-borne illness. The Egg Safety Center and the Food and Drug Administration recommend that eggs should be fully cooked until both the yolks and the whites are firm, and consumers should not eat foods that may contain raw or undercooked eggs. For more information on proper handling and preparation of eggs and answers to other frequently asked questions, visit www.eggsafety.org.

The chance of an egg containing Salmonella Enteritidis is rare in the United States. Several years ago, it was estimated that 1 in 20,000 eggs might have been contaminated, which meant most consumers probably wouldn’t come in contact with such an egg but 1 time in 84 years. Since that time most U.S. egg farmers have been employing tougher food safety measures to help protect against food-borne illness. Chief among these methods are modern, sanitary housing systems; stringent rodent control and bio-security controls; inoculation against Salmonella Enteritidis; cleaning and sanitization of poultry houses and farms; and testing.

About the Egg Safety Center

The Egg Safety Center provides scientifically accurate information on food safety issues related to eggs. We work with egg producers to provide them with the most up to date information available and are dedicated to educating consumers on proper food handling to reduce the incidence of food-borne illness. For more information on egg safety visit www.eggsafety.org.

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. crwenewswire.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer (read more) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold crwenewswire.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

CORAL GABLES, Fla., Aug. 6, 2010 (CRWENEWSWIRE) — Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced that it has entered into definitive agreements to sell 1,351,352 shares of its common stock at a price per share of $1.11 pursuant to a registered direct offering to two large mutual funds, representing gross proceeds of $1.5 million.

The closing of the offering is expected to take place on August 9, 2010, subject to the satisfaction of customary closing conditions. Catalyst intends to use the proceeds from the offering for general corporate purposes.

The shares are being offered by Catalyst Pharmaceutical Partners, Inc. pursuant to a shelf registration statement filed with the Securities and Exchange Commission that was declared effective on June 26, 2008.

Patrick J. McEnany, Catalyst’s Chief Executive Officer, said, “We expect that this financing will provide sufficient capital for Catalyst to operate into early 2012 and through the announcement of top-line results of our CPP-109 U.S. Phase II(b) cocaine trial.”

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a development-stage biopharmaceutical company focused on the development and commercialization of prescription drugs targeting addiction and other diseases of the central nervous system such as epilepsy and neuropathic pain. Catalyst has two products in development, and is currently evaluating the lead product candidate, CPP-109 (vigabatrin, a GABA aminotransferase inhibitor) for the treatment of cocaine addiction. CPP-109 has been granted “Fast Track” status by the U.S. Food & Drug Administration (FDA) for the treatment of cocaine addiction, which indicates that the FDA has recognized that CPP-109 is intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrates the potential to address an unmet medical need. Catalyst also expects to evaluate CPP-109 for the treatment of other addictions and obsessive-compulsive disorders. Catalyst is also in the early stages of developing CPP-115, another GABA aminotransferase inhibitor that could be more potent than vigabatrin but may have reduced side effects (e.g., visual field defects, or VFDs) from those associated with vigabatrin. Catalyst is planning to develop CPP-115 for several indications including drug addiction, epilepsy and neuropathic pain. Catalyst believes that it controls all current intellectual property for drugs that have a mechanism of action related to GABA aminotransferase. For more information about the Company, go to www.catalystpharma.com.

Contact:

Catalyst Pharmaceutical Partners, Inc.
Jack Weinstein, Chief Financial Officer
(201) 934-4201
jweinstein@catalystpharma.com
Rx Communications
Melody Carey
(917) 322-2568
mcarey@rxir.com

Disclaimer:
The Views and Opinions Expressed by the author are his or her opinions only and do not necessarily reflect those of Crown Equity Holdings or its agents, affiliates, officers, directors, staff, or contractors. The author at the time of this article did not own any shares or receive any consideration financial or otherwise from any company mentioned or referred to in the article.

By Mike Zaman

Alfred Sapse now 84 is a less than colorful Las Vegas Character, over the years he has been involved in numerous lawsuits including several with a public company STGI.

In one of the STGI Lawsuits Mr. Sapse was required to return shares of STGI stock he was alleged to have obtained through a fraudulent drug formula scheme.

In each lawsuit their have been a common denominator Mr. Sapse has been a defendant facing allegations of Fraud in one form or another. In one case Mr. Sapse had sued claiming the defendant was responsible for the death of his wife Renee, she was alive at the time.

Complaints over the years were filed with the Nevada State Attorney Generals office, and the District Attorney for Clark County, however they had no interest in pursuing Mr. Sapse as the claims filed by Las Vegas residents amounted to only a bit more than $1.2 million.

The final clincher

In the past 4 years Mr. Sapse was sued for Fraud over his representations that he had invented a drug formula that a pharmaceutical company Valiant had agreed to acquire for $25,000,000 based on this representation, which Valiant denies, Mr. Sapse obtained money from investors for one of his several corporations “Cortisol Research International” No drug was ever sold! And investors were never repaid.

It seems that Mr. Sapse over the years has gone from one form of “business” to another without any state authority attempting to stop him. We wonder why?

It took the Federal Government to finally step in, but after more than 100 chronically ill people were treated by Mr. Sapse who by the way lacks a medical license. However a medical license aside, Mr. Sapse was able to get investors and patients to pay him more than $1.7 million, which seems to have lined the pockets of several local casinos.

Now comes time to pay the piper; Mr. Sapse was indicted on seven counts of mail fraud, 13 counts of wire fraud and criminal forfeiture of $913,748.

Mr. Sapse was arrested in Las Vegas by special agents with the U.S. Food and Drug Administration Office of Criminal Investigations and appeared before a federal magistrate judge. He was released on a personal recognizance bond pending trial, Mr Sapse if convicted faces up to 20 years in prison and a $250,000 fine on each count, and forfeiture of money or property up to $913,748.

The investigation has been going on for more than one year. Mr. Sapse will be prosecuted by Assistant U.S. Attorneys Crane Pomerantz and Patrick Walsh

********************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWENewswire.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWENewswire.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more) Rule 17B requires disclosure of payment for investor relations.